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ABSTRACT
Dengue virus (DENV) is the leading mosquito-transmitted viral infection in the world. With more than 390
million new infections annually, and up to 1 million clinical cases with severe disease manifestations, there
continues to be a need to develop new antiviral agents against dengue infection. In addition, there is no
approved anti-DENV agents for treating DENV-infected patients. In the present study, we identified new
compounds with anti-DENV replication activity by targeting viral replication enzymes – NS5, RNA-depend-
ent RNA polymerase (RdRp) and NS3 protease, using cell-based reporter assay. Subsequently, we per-
formed an enzyme-based assay to clarify the action of these compounds against DENV RdRp or NS3
protease activity. Moreover, these compounds exhibited anti-DENV activity in vivo in the ICR-suckling
DENV-infected mouse model. Combination drug treatment exhibited a synergistic inhibition of DENV repli-
cation. These results describe novel prototypical small anti-DENV molecules for further development
through compound modification and provide potential antivirals for treating DENV infection and DENV-
related diseases.
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Introduction
Dengue virus (DENV) is responsible of worldwide arthropodborne
viral infection, which globally represents a serious human health
concern. DENV is the etiological agent of disease in more than
hundred countries with up to 3 billion people exposed to the risk
of infection in the tropical regions1–3. DENV has expanded its glo-
bal range with sustained outbreaks in South America and Asia,
with these epidemics accompanied by increased disease severity.
DENV are single-stranded, positive sense RNA viruses belonging
to the Flaviviridae family. The DENV family can be viewed as falling
in four related, but antigenically distinct, DENV 1–4 serotypes. The
carriers of DENV to humans are the mosquitoes Aedes aegypti and
Aedes albopictus. The DENV infection causes a variety of illness,
including asymptomatic or subclinical disease, dengue fever (DF)
symptoms and the most severe dengue haemorrhagic fever (DHF)
and dengue shock syndrome (DSS) which cause millions of infec-
tions around the world4–8. DENV has a 10.7 kb, positive-sense RNA
genome with 50- and 30-untranslated regions flanking a polypro-
tein that encodes three structural (C, prM/M and E) and seven
non-structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) pro-
teins. prM and E structural proteins are the primary antigenic tar-
gets of the humoural immune response in humans9–12. DENV NS3
is a multifunctional protein, which contains protease, helicase and
triphosphatase domain. The N-terminal amino acids (residue
1–184) of NS3 is responsible for protease activity. NS2B serves as a
cofactor of NS3 protease and forms complex with NS3; the central
amino acid hydrophilic domain (residue 49–92) of NS2B is critical
for cofactor activity13. DENV replication also requires the non-
structural protein 5 (NS5) which is the essential RNA-dependent
RNA polymerase (RdRp) activity14. DENV NS5 RdRp has proven to
be a promising target for direct-acting antiviral (DAA) drug devel-
opment, because it is structurally conserved among the four DENV
serotypes, and NS5 RdRp has no enzymatic counterpart in mam-
malian cells15.
Currently, no licensed antiviral drugs are available to block
DENV infection, and while vector control efforts remain the only
means to stop the spread of the infection, they have not success-
fully inhibited annual epidemic outbreaks throughout the
tropics16. Recently, a live-attenuated DENV vaccine17 based on
the yellow fever virus 17D backbone was licensed for use in the
Philippines, Brazil and Mexico. However, the serotype-specific effi-
cacy of the DENV vaccine is varying, and the long-term protection
and safety of this vaccine still need more investigation18. In the
present study, we have focused on the identification of potential
anti-DENV inhibitors by targeting the enzymatic activities of the
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NS5 RdRp polymerase and NS3 protease in vitro and in vivo19–21.
As part of a continuation of our studies22–24, we developed new
pyrazole derivatives25 as potential DENV NS5 RdRp inhibitors
(Table 1). In addition, we carried out virtual screening (VS) studies
on the NS2B/NS3 protease to design and synthesise new DENV
NS3 protease inhibitors (Table 2). In sum, we identified five
compounds that exhibited anti-DENV replication activity without
cytotoxicity; two compounds exhibited anti-DENV activity in DENV-
infected ICR-suckling mouse model. Interestingly, combination
treatment with compounds, respectively, targeting NS5 RdRp poly-
merase and NS3 protease, demonstrated a synergistic inhibitory
effect on DENV replication.
Materials and methods
Chemistry
Microwave (MW)-assisted reactions were performed on a CEM
Discover SP single-mode reactor equipped with Explorer 72 auto-
sampler, controlling the instrument settings by PC-running CEM
Synergy 1.60 software (Matthews, NY, USA). Closed vessel experi-
ments were carried out in capped MW-dedicated vials (10ml) with
cylindrical stirring bar (length 8mm, diameter 3mm). Stirring, tem-
perature, irradiation power, maximum pressure (Pmax), PowerMAX
(simultaneous cooling while heating), ActiVent (simultaneous vent-
ing while heating), and ramp and hold times were set as indi-
cated. Temperature of the reaction was monitored by an external
fibre optic temperature sensor. After completion of the reaction,
the mixture was cooled to 25 C via air jet cooling. Organic solu-
tions were dried over anhydrous sodium sulphate. Evaporation of
the solvents was carried out on a Bu€chi Rotavapor R-210 equipped
with a Bu€chi V-850 vacuum controller and a Bu€chi V-700 vacuum
pump. Column chromatography was performed on columns
packed with silica gel from Macherey-Nagel (70 230 mesh). Silica
gel thin-layer chromatography (TLC) cards from Macherey-Nagel
(silica gel pre-coated aluminium cards with fluorescent indicator
visualisable at 254 nm) were used for TLC. Developed plates were
visualised with a Spectroline ENF 260C/FE UV apparatus. Melting
points (mp) were determined on a Stuart Scientific SMP1 appar-
atus and are uncorrected. Infrared spectra (IR) were run on a
PerkinElmer Spectrum 100 FT-IR spectrophotometer equipped with
universal attenuated total reflectance (ATR) accessory and IR data
acquired and processed by PerkinElmer Spectrum 10.03.00.0069
software. Band position and absorption ranges are given in cm1.
Proton nuclear magnetic resonance (1H NMR) spectra were
recorded a Bruker Avance (400MHz) spectrometer in the indicated
solvent and corresponding fid files were processed by MestreLab
Research SL MestreReNova 6.2.1–769 software (Santiago de
Compostela, Spain). Chemical shifts are expressed in d units (ppm)
from tetramethylsilane. Elemental analyses of biologically eval-
uated compounds were found to be within ±0.4% of the theoret-
ical values and their purity was found to be >95% by high-
pressure liquid chromatography (HPLC). The HPLC system used
Thermo Fisher Scientific Dionex UltiMate 3000, consisted of a SR-
3000 solvent rack, a LPG-3400SD quaternary analytical pump, a
TCC-3000SD column compartment, a DAD-3000 diode array
Table 1. Activity of Compounds 1–3 against DENV-2 Replication and DENV-2 NS5 RdRp.
DENV-2a
RNA NS5 RdRp
Structure CC50
b (lM) EC50
c ± SD (lM) SId Cell-based EC50
e ± SD (lM) Enzyme-based EC50
f ± SD (lM)
1
N N
N
Me
S
S
Cl
O
O
O
O
EtO O
Cl
196 11.7 ± 0.2 16.7 8.1 ± 0.3 7.8 ± 0.3
2
N N NH
Me SO
O
EtO
O
N
O
>200 7.6 ± 0.4 >26.3 7.2 ± 0.4 5.3 ± 0.2
3
N N
N
S
S
NO2
O
O
O
O
EtO O
NO2
>200 5.7 ± 0.3 >35.1 6.0 ± 0.3 4.9 ± 0.2
aData are mean values of two to three independent experiments each one in triplicate.
bCC50: half maximal cytotoxicity concentration.
cEC50 (DENV-2 RNA): half maximal effective concentration. Huh-7 cells were infected with DENV-2 and followed by RdRp inhibitors treatment for 3 days. The cell
lysates were collected to analyse DENV RNA synthesis by qRT-PCR with specific primers targeting NS5.
dSI: selectivity index calculated as CC50/EC50 ratio.
eEC50 (cell-based DENV-2 NS5 RdRp): cell-based RdRp reporter assay. The Huh-7 cells were transiently expressed p(þ)RLuc-(–)DV-UTRDC-FLuc and DENV NS5 expres-
sion vector pcDNA-NS5-Myc.
fEC50 (enzyme-based DENV-2 NS5 RdRp): enzyme-based RdRp activity assay. The () 30UTR RNA was incubated with RdRp polymerase protein and CTP, GTP, UTP and
BBT-ATP. The fluorescence signal was measured at excitation wavelength of 422 nm and emission wavelength of 566 nm, respectively.
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detector and an analytical manual injection valve with a 20 mL
loop. Samples were dissolved in acetonitrile (1mg/mL). HPLC ana-
lysis was performed by using a Thermo Fisher Scientific Acclaim
120 C18 column (5 mm, 4.6mm 250mm) at 25± 1 C with an
appropriate solvent gradient (acetonitrile/water), flow rate of
1.0mL/min and signal detector at 206, 230, 254 and 365 nm.
Chromatographic data were acquired and processed by Thermo
Fisher Scientific Chromeleon 6.80 SR15 Build 4656 software
(Waltham, MA, USA).
General procedure for preparation of compounds 1, 3 and 8.
Ethyl 5–(4-chloro-N-((4-chlorophenyl)sulphonyl)phenylsulphonamido)-
1-methyl-1H-pyrazole-4-carboxylate (1). 4-Chlorobenzenesulphonyl
chloride (0.15 g, 0.72mmol) was added to solution of commercially
available 6 (0.10 g, 0.6mmol) in pyridine (2mL) while stirring. The
reaction was stirred at 60 C overnight. The mixture was neutral-
ised with 1N HCl and extracted with ethyl acetate. The organic
layer was washed with brine, dried and filtered. Removal of the
solvent gave a residue that was purified by column chromatog-
raphy (silica gel, n-hexane:ethyl acetate¼ 2:1 as eluent) to furnish
1 (0.10 g, 33%), mp 132–135 C (from ethanol). 1H NMR (DMSO-d6):
d 0.96 (t, J¼ 6.2 Hz, 3H), 3.52 (s, 3H), 3.71–3.77 (m, 2H), 7.81 (d,
J¼ 8.0 Hz, 4H), 7.94 (d, J¼ 7.9 Hz, 4H), 8.06 ppm (s, 1H). FT-IR (ATR):
 1176, 1391, 1709 cm1. Anal. calcd. for C19H17Cl2N3O6S2 (518.38):
C, 44.02; H, 3.31; N, 8.11; Cl, 13.68; S, 12.37. Found: C, 43.78; H,
3.26; N, 7.84; Cl, 13.36; S, 12.02.
Ethyl 5–(4-nitro-N-((4-nitrophenyl)sulphonyl)phenylsulphonamido)-
1-phenyl-1H-pyrazole-4-carboxylate (3). Was synthesised as 1 starting
from 726 and 4-nitrobenzensulphonyl chloride. Yield 79%, mp
230–232 C (from ethanol). 1H NMR (DMSO-d6): d 1.01 (t, J¼ 7.0, 3H),
3.70–3.76 (m, 2H), 7.32–7.38 (m, 3H), 7.48 (d, J¼ 6.9 Hz, 2H), 8.04 (d,
J¼ 8.9 Hz, 4H), 8.33–8.36 ppm (m, 5H). FT-IR (ATR):  1167, 1336,
1597, 1706 cm1. Anal. calcd. for C24H19N5O10S2 (601.06): C, 47.92; H,
3.18; N, 11.64; S, 10.66. Found: C, 47.78; H, 3.11; N, 11.39; S, 10.42.
Ethyl 1-methyl-5–(4-nitro-N-((4-nitrophenyl)sulphonyl)phenylsul-
phonamido)-1H-pyrazole-4-carboxylate (8). Was synthesised as 1
starting from 6 and 4-nitrobenzenesulphonyl chloride. Yield 33%,
mp 220–222 C (from ethanol). 1H NMR (DMSO-d6): d 0.93
(t, J¼ 7.1 Hz, 3H), 3.54 (s, 3H), 3.69–3.74 (m, 2H), 8.11 (s, 1H), 8.23
(d, J¼ 8.9 Hz, 4H), 8.52 ppm (d, J¼ 8.9 Hz, 4H). FT-IR (ATR):  1173,
1349, 1528, 1717 cm1. Anal. calcd. for C19H17N5O10S2 (539.49): C,
42.30; H, 3.18; N, 12.98; S, 11.89. Found: C, 42.12; H, 3.14; N, 12.60;
S, 11.70.
Ethyl 1-methyl-5–(4-nitrophenylsulphonamido)-1H-pyrazole-4-carb-
oxylate (9). A mixture of 8 (0.032 g, 0.06mmol) and lithium hydrox-
ide monohydrate (0.01 g, 0.24mmol) in THF/H2O (1:1, 5mL) was
heated at 50 C for 15min, cooled, made acid with 1 N HCl aqueous
solution (pH 5) and extracted with ethyl acetate. The organic layer
was washed with brine, dried and filtered. Removal of the solvent
gave 9 (0.02 g, 95%), mp 150–152 C (from ethanol). 1H NMR
(DMSO-d6): d 0.98 (t, J¼ 7.08, 3H), 3.71–3.76 (m, 5H), 7.78 (s, 1H),
7.87 (d, J¼ 8.9 Hz, 2H), 8.40 (d, J¼ 8.9 Hz, 2H), 11.01 ppm (br s, dis-
appeared on treatment with D2O, 1H). FT-IR (ATR):  1170, 1347,
1532, 1709 cm1. Anal. calcd. for C13H14N4O6S (354.34): C, 44.07; H,
3.98; N, 15.81; S, 9.05. Found: C, 43.84; H, 3.92; N, 15.62; S, 8.91.
Ethyl 5–(4-aminophenylsulphonamido)-1-methyl-1H-pyrazole-4-
carboxylate (10). A mixture of 9 (0.14 g, 0.4mmol) and tin(II) chlor-
ide dihydrate (0.27 g, 1.2mmol) in ethyl acetate (15ml) was heated
at reflux for 3 h. After cooling, the mixture was made basic
(pH 8) with a saturated aqueous solution of NaHCO3 and filtered.
The layers were separated and the organic one was washed with
brine, dried and filtered. Removal of the solvent gave a residue
that was purified by column chromatography (silica gel,
dichloromethane:ethanol¼ 9.8:0.2 as eluent) to furnish 10 (0.06 g,
50%), mp 118–120 C (from ethanol). 1H NMR (DMSO-d6): d 1.09 (t,
J¼ 7.1 Hz, 3H), 3.66 (s, 3H), 3.83–3.88 (m, 2H), 6.02 (s, 2H), 6.52 (d,
J¼ 8.7 Hz, 2H), 7.20 (d, J¼ 8.7 Hz, 2H), 7.72 (s, 1H), 9.71 ppm (br s,
disappeared on treatment with D2O, 1H). FT-IR (ATR):  1152,
1378, 1698, 3397 cm1.
Ethyl 5–(4-(1H-pyrrol-1-yl)phenylsulphonamido)-1-methyl-1H-pyra-
zole-4-carboxylate (11). A mixture of 10 (0.05 g, 0.15mmol) and
Table 2. Activity of DENV inhibitors 4 and 5 against DENV-2 replication.
DENV-2a
RNA NS3
Structure CC50
b (lM) EC50
c ± SD (lM) SId Cell-based EC50
e ± SD (lM) Enzyme-based EC50
f ± SD (lM)
4 181 4.6 ± 0.3 39.3 6.7 ± 0.2 4.7 ± 0.3
5 >200 7.3 ± 0.3 27.4 7.9 ± 0.6 6.9 ± 0.4
aData are mean values of two to three independent experiments each one in triplicate.
bCC50: half maximal cytotoxicity concentration.
cEC50 (DENV-2 RNA): half maximal effective concentration. Huh-7 cells were infected with DENV-2 and followed by RdRp inhibitors treatment for 3 days. The cell
lysates were collected to analyse DENV RNA synthesis by qRT-PCR with specific primers targeting NS5.
dSI: selectivity index calculated as CC50/EC50 ratio.
eEC50 (cell-based DENV-2 NS3 protease): Huh-7 cells were transfected with pEG(MITA)SEAP and pcDNA-NS2B-GSG-NS3-Myc followed by incubation of each compound.
The SEAP activity was measured by Phodpha-Light assay kit after 3 days post incubation.
fEC50 (enzyme-based DENV-2 NS3 protease). The 7-amino-4-methylcoumarin (AMC) fluorophore-linked peptide substrate Boc-GRR-AMC (Bachem, USA) was incubated
with DENV NS2B/NS3pro protein and compound. The fluorescence signal was detected at excitation wavelength of 380 nm and emission wavelength of 465 nm,
respectively.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 1093
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 St
ud
i la
 Sa
pie
nz
a] 
at 
09
:38
 28
 N
ov
em
be
r 2
01
7 
2,5-dimethoxytetrahydrofuran (0.02 g, 0.02mL, 0.15mmol) in gla-
cial acetic acid (1mL) was heated at reflux for 30min. The solvent
was removed in vacuo, and after cooling water and ethyl acetate
were added. Layers were separated and the organic one was
washed with a saturated aqueous solution of NaHCO3, brine and
dried. Removal of the solvent gave a residue that was purified by
column chromatography (silica gel, n-hexane:ethyl acetate¼ 1:1 as
eluent) to furnish 11 (0.035 g, 66%), mp 200–203 C (from ethanol).
1H NMR (DMSO-d6): d 0.97 (t, J¼ 7.1 Hz, 3H), 3.73–3.77 (m, 5H),
6.32 (t, J¼ 2.2 Hz, 2H), 7.49 (t, J¼ 2.2 Hz, 2H), 7.62 (d, J¼ 8.8 Hz,
2H), 7.76–7.78 (m, 3H), 10.48 ppm (br s, disappeared on treatment
with D2O, 1H). FT-IR (ATR):  1132, 1336, 1702, 3139 cm
1. Anal.
calcd. for C17H18N4O4S (374.41): C, 54.53; H, 4.85; N, 14.96; S, 8.56.
Found: C, 54.28; H, 4.79; N, 14.69; S, 8.22.
Ethyl 5–(4-(2-benzoyl-1H-pyrrol-1-yl)phenylsulphonamido)-1-
methyl-1H-pyrazole-4-carboxylate (2). A mixture of 11 (0.06 g,
0.14mmol), benzoyl chloride (0.02 g, 0.016mL, 0.14mmol) and
anhydrous aluminium chloride (0.02 g; 0.14mol) in anhydrous 1,2-
dichloroethane (3mL) was placed into the MW cavity (closed ves-
sel mode, Pmax¼ 250 psi). A starting MW irradiation of 70 W was
used, the temperature being ramped from 25 to 110 C, while stir-
ring. Once 110 C was reached, taking about 1min, the reaction
mixture was held at this temperature for 4min. The reaction mix-
ture was quenched on 1N HCl aqueous solution/crushed ice and
extracted with dichloromethane. The organic layer was washed
with brine, dried and filtered. Removal of the solvent gave a resi-
due that was purified by column chromatography (silica gel,
n-hexane:acetone¼ 2:1 as eluent) to furnish 2 (0.04 g, 71%), mp
136–140 C (from ethanol). 1H NMR (DMSO-d6): d 1.07 (t, J¼ 7.1 Hz,
3H), 3.67 (s, 3H), 3.87–3.93 (m, 2H), 6.43–6.45 (m, 1H), 6.87–6.89
(m, 1H), 7.45–7.46 (m, 1H), 7.52–7.56 (m, 4H), 7.63–7.69 (m, 3H),
7.78 (s, 1H), 7.82–7.84 (m, 2H) 10.60 ppm (br s, disappeared on
treatment with D2O, 1H). FT-IR (ATR):  1166, 1347, 1595, 1713,
3102 cm1. Anal. calcd. for C24H22N4O5S (478.52): C, 60.24; H, 4.63;
N, 11.71; S, 6.70. Found: C, 59.92; H, 4.58; N, 11.46; S, 6.46. Further
elution with the same eluent gave ethyl 5–(4-(3-benzoyl-1H-pyrrol-
1-yl)phenylsulphonamido)-1-methyl-1H-pyrazole-4-carboxylate (0.02 g,
28%), mp 216–218 C (from ethanol). 1H NMR (DMSO-d6): d 0.97
(t, J¼ 7.0 Hz, 3H), 3.73–3.79 (m, 5H), 6.80–6.82 (m, 1H), 7.53–7.57
(m, 2H), 7.62–7.68 (m, 4H), 7.76 (s, 1H), 7.84–7.86 (d, J¼ 8.4 Hz, 2H),
7.93–7.96 (d, J¼ 9.0 Hz, 2H), 8.04 (s, 1H), 10.58 ppm (br s, disap-
peared on treatment with D2O, 1H). FT-IR (ATR):  1166, 1280,
1642, 1706, 3132 cm1. Anal. calcd. C24H22N4O5S (478.52): C, 60.24;
H, 4.63; N, 11.71; S, 6.70. Found: C, 59.88; H, 4.55; N, 11.65; S, 6.60.
Methyl 5-chloro-3–(4-hydroxy-3,5-dimethoxybenzoyl)-1H-indole-2-
carboxylate (4). Was synthesised as 2 starting from 12 and 4-
hydroxy-3,5-dimethoxybenzoyl chloride. Yield 11%, mp 118–120 C
(from ethanol). 1H NMR (CDCl3): d 3.70 (s, 3H), 3.86 (s, 6H), 6.01 (br
s, disappeared on treatment with D2O, 1H), 7.17 (s, 2H), 7.32–7.35
(m, 1H), 7.41–7.43 (m, 1H), 7.60–7.61 (m, 1H), 9.31 ppm (br s, disap-
peared on treatment with D2O, 1H). FT-IR (ATR):  1715,
3312 cm1. Anal. calcd. for C19H16ClNO6 (389.79): C, 58.55; H, 4.14;
N, 3.59; Cl, 9.09. Found: C, 58.36; H, 4.09; N, 3.23; Cl, 8.81.
Methyl 5-chloro-3–(3,5-dimethoxybenzoyl)-1H-indole-2-carboxylate
(13). Was synthesised as 2 starting from 12 and 3,5-dimethoxyben-
zoyl chloride. Yield 21%, mp 185–188 C (from ethanol). 1H NMR
(CDCl3): d 3.70 (s, 3H), 3.82 (s, 6H), 6.07 (t, J¼ 2.3 Hz, 1H), 7.0 (d,
J¼ 4.7 Hz, 2H), 7.33–7.36 (m, 1H), 7.41–7.44 (m, 1H), 7.65–7.66 (m,
1H), 9.31 ppm (br s, disappeared on treatment with D2O, 1H). FT-IR
(ATR):  1698, 3287 cm1.
Methyl 5-chloro-3–(3,5-dimethoxybenzyl)-1H-indole-2-carboxylate
(5). A mixture of 13 (0.1 g, 0.3mmol), triethylsilane (0.072 g, 0.1mL,
0.6mmol) and trifluoroacetic acid (0.31 g, 0.21mL, 3mmol) was
stirred at 25 C for 48 h. The mixture was diluted with a saturated
aqueous solution of NaHCO3 and extracted with ethyl acetate. The
organic layer was washed with brine, dried and filtered. Removal
of the solvent gave a residue that was purified by column chroma-
tography (silica gel, n-hexane/ethyl acetate¼ 3:1 as eluent) to fur-
nish 5 (0.05 g, 50%), mp 182–185 C (from ethanol). 1H NMR
(CDCl3): d 3.71 (s, 6H), 3.92 (s, 3H), 4.43 (s, 2H), 6.30–6.31 (m, 1H),
6.41–6.44 (m, 2H), 7.25–7.35 (m, 2H), 7.58–7.60 (m, 1H), 8.80 ppm
(br s, disappeared on treatment with D2O, 1H). FT-IR (ATR):  1690,
3323 cm1. Anal. calcd. for C19H18ClNO4 (359.81): C, 63.43; H, 5.04;
Cl, 9.85; N, 3.89. Found: C, 63.27; H, 4.97; Cl, 9.59; N, 3.70.
Molecular modelling studies
All molecular modelling studies were performed on a MacPro dual
2.66 GHz Xeon running Ubuntu 12. The DENV protease structure
(PDB ID: 2FOM)27 was downloaded from the protein data bank. An
in-house compound library matching Lipinski’s rule of five28 was
used as a training set. No pre-filter was applied. The docking simu-
lations were performed with PLANTS29 using a 13 Å radius grid
sphere. The centre of the binding site was settled according to
Tamiri30. Molecules were scored by ChemPLP scoring function.29
Figure 1 was generated by PyMOL31.
Ethics statement and experimental animals
Six-day-old ICR strain-suckling mice were obtained from BioLasco
Taiwan Co. Ltd (Taipei, Taiwan). All animal studies were conducted
in specific pathogen-free conditions and carried out in accordance
with the Guide for the Care and Use of Laboratory Animals. The
experimental protocol was approved by the Animal Research
Committee of Kaohsiung Medical University of Taiwan (IACUC,
protocol number 102177) under the guidance of the Public Health
Service (PHS) Policy on Humane Care and Use of Laboratory
Animals.
Cells and virus
Human hepatoma Huh-7 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 10% foetal bovine serum,
1% non-essential amino acids, and 1% antibiotic–antimycotic
within 5% CO2 supplement at 37 C. Aedes albopictus C6/36 mos-
quito cells were cultured in RPMI1640 medium containing 10%
fetal bovine serum, 1% non-essential amino acids, 1% antibioti-
c–antimycotic and 1% sodium pyruvate within 5% CO2 supple-
ment at 37 C. DENV-2 (DENV type-2 strain 16681) was amplified
in C6/36 mosquito cells. Spodoptera frugiperda (Sf9) insect cells
were cultured in Grace’s medium with 10% hear-inactivated foetal
bovine serum (FBS) and 1% antibiotic–antimycotic at 26 C.
Evaluation of anti-DENV RNA activity
Huh-7 cells were seeded in 24-well plate and infected DENV at an
MOI of 0.2 for 2 h and followed by test compound treatment at
concentration of 0, 1, 5, 10, 25, 50 and 100 mM for 3 days. The total
cellular RNA was harvested by RNA extraction kit32 following man-
ufacturer’s instrument. DENV RNA and cellular mRNA levels were
determined by quantitative real-time reverse-transcription poly-
merase chain reaction (RT-qPCR) with specific primers33. The DENV
RNA level was normalised by cellular glyceraldehydes-3-phosphate
dehydrogenase (GAPDH) mRNA level. The relative DENV RNA level
was calculated by StepOneTM Software v2.2.2 (Applied Biosystems,
Foster City, CA, USA) following normalisation of cellular
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glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA level.
The zero dose was defined as 100%. The EC50 values were calcu-
lated from non-linear regression curve fitting using GraphPad
Prism7 software (San Diego, CA, USA). Results were obtained from
three independent experiments.
Cell cytotoxicity assay
The Huh-7 cells were seeded in 96-well and treated with test com-
pound at concentration of 0, 10, 25, 50, 100, 150 and 200mM.
After 3 days incubation, the cell viability was determined by
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS
assay) as previously reported34. Briefly, the MTS assay buffer was
added to the cultured plate following removal of the culture
medium. After 2 h of incubation at 37 C, the absorbance at
492 nm was measured. The cell viability was calculated from non-
linear regression curve fitting using GraphPad Prism7. The zero
dose was defined as 100%. Results were obtained from three inde-
pendent experiments.
Purification of DENV NS5 protein
The DENV-2 NS5 protein purification was performed as previously
described33. Briefly, Sf9 cells were infected by the recombinant
baculovirus vAc-DENV-NS5 at an MOI of 10 for 3 days. The cells
were pelleted by centrifugation at 1000g for 5min at 4 C and
washed twice with phosphate-buffered saline (PBS). The cells were
suspended in 5mL of binding buffer (20mM sodium phosphate,
pH 7.5, 300mM NaCl, 20mM imidazole) containing protease
inhibitor cocktail, and then disrupted by sonication. After centrifu-
gation, the supernatant containing His-tagged DENV-2 NS5 protein
was subjected to metal affinity chromatography employing the
AKTA prime protein purification system35. The eluted DENV-2 NS5
protein was concentrated by an Amicon Ultra-15 30 k centrifugal
filter device36 and then dialysed against PBS overnight at 4 C.
Evaluation of anti-DENV RdRp activity
The cell-based experiments were performed as previously
described33. Briefly, the Huh-7 cells were transfected with 0.5mg of
p(þ)RLuc-(–)DV-UTRDC-FLuc and DENV NS5 expression vector
pcDNA-NS5-Myc followed by compound treatment for 3 days. The
RLuc and FLuc activities were analysed by Dual-Glo Luciferase
Assay System37. The enzyme-based fluorescence-based alkaline
phosphatase-coupled polymerase assay (FAPA) was performed as
previously described33. Briefly, the template was amplified from
the cDNA of DENV-2 minus strand 30-UTR and its RNA was syn-
thesised by the T7 Megascript kit38. The 100 nM DENV NS5 protein
was incubated with 1, 5 or 10mM test compound, 100 nM () 30-
UTR RNA, 20 mM CTP, GTP, UTP and 20 mM BBT-ATP (Jena
Bioscience) in a total volume of 30mL in assay buffer (50mM Tris-
HCl, pH 7.5, 10mM KCl, 1mM MgCl2, 0.3mM MnCl2, 0.001% Triton
X-100 and 10mM cysteine) at 25 C for 60min. The 30mL of 2.5
stop buffer (200mM NaCl, 25mM MgCl2, 1.5 M diethanolamine,
pH 10) with 25 nM calf intestinal alkaline phosphatase (Promega)
was added to the reaction after 60-min incubation. The fluores-
cence signal was measured at excitation wavelength of 422 nm
and emission wavelength of 566 nm, respectively.
Purification of DENV NS2B/NS3pro protein
The DENV NS2B/NS3pro purification was performed as previously
described39. Briefly, the pET24b-NS2B-NS3pro plasmid was
Figure 1. Proposed binding for derivatives 4 (green) and 5 (magenta). Residues involved in interactions are reported as cyan stick. H-bonds are shown as yellow dot
lines. Protease is reported as cartoon: grey for NS3 and red for NS2 subunits.
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transformed into competent Escherichia coli BL21 (DE3) and grew
in kanamycin (50 mg/mL)-containing LB at 26 C until OD600 nm
reached 0.6. The isopropyl-b-D-thiogalactopyranose was
added into the bacterial culture at 0.5mM for protein induction.
After 12-h incubation, cells were collected and subjected to pro-
tein purification following previous description.
Evaluation of anti-DENV protease activity
For cell-based activity assay, the Huh-7 cells were cotransfected
with 0.5mg of pEG(MITA)SEAP reporter vector and DENV protease
expression vector pcDNA-NS2B-GSG-NS3-Myc followed by com-
pound treatment for 3 days. The SEAP activity was analysed by
Phospha-Light SEAP Reporter Gene Assay System40. The enzyme-
based experiment was performed as previously described39.
Briefly, the 7-amino-4-methylcoumarin (AMC) fluorophore-linked
peptide substrate Boc-GRR-AMC41 and purified DENV NS2B/
NS3pro protein were used to analyse DENV NS2B/NS3 protease
activity. The 100 nM DENV NS2B/NS3pro protein was incubated
with 1, 5 or 10 mM tested compound and 10 mM Boc-GRR-AMC in
cleavage buffer (200mM Tris [pH 9.5], 20% glycerol) for 30min at
25 C. The fluorescence signal was detected at excitation wave-
length of 380 nm and emission wavelength of 465 nm,
respectively.
Evaluation of anti-DENV activity by ICR-suckling mice
Breeder ICR mice were purchased from BioLasco Taiwan Co.
Ltd. The experimental protocol was approved by the Animal
Research Committee of Kaohsiung Medical University of Taiwan
(IACUC, protocol number 102177). All mice received humane
care and fed with standard rodent chew and water ad libitum.
Mice were kept under a standard laboratory condition following
the Animal Use Protocol of Kaohsiung Medical University. The
6-day-old ICR-suckling mice were intracerebrally injected with
DENV-2 followed by intracerebrally injecting saline or test com-
pound at 1, 3, 5 days postinfection (dpi). Mice intracerebrally
injected with 65 C heat-inactive DENV-2 followed with saline
treatment served as healthy control. The body weight, clinical
scores and survival rate were recorded every day. The mice
were sacrificed at 6 dpi.
Results and discussion
Chemistry
Compounds 1–3 were synthesised as shown in Scheme 1. Ethyl
5-amino-1-methyl-1H-pyrazole-4-carboxylate (6) was purchased
from Maybridge. Treatment of ethyl 2-cyano-3-ethoxyacrylate with
phenylhydrazine hydrochloride yielded ethyl 5-amino-1-phenylpyr-
azole-4-carboxylate (7)26. Pyrazoles 6 and 7 were converted into
final derivatives 1, 3 or intermediate 8 by reaction with 4-chloro-
or 4-nitrobenzenesulphonyl chloride, respectively, in pyridine.
Treatment of 8 with lithium hydroxide in aqueous tetrahydrofuran
for 15min gave the sulphonamide 9. Tin (II) chloride dihydrate
reduction of 9 for 3 h in boiling ethyl acetate afforded amino
derivative 10 that was converted into pyrrole derivative 11 with
2,5-dimethoxytetrahydrofuran in glacial acetic acid at 80 C for 1 h.
Derivative 2 was prepared from 11 by MW-assisted reaction with
benzoyl chloride in the presence of anhydrous aluminium chloride
in 1,2-dichloroethane at 110 C (70W) for 3min.
Indole derivatives 4 and 5 were synthesised as shown in
Scheme 2. Final compound 4 and the intermediate 13 were pre-
pared by MW-assisted aroylation of methyl 5-chloro-1H-indole-2-
carboxylate (12) with 4-hydroxy-3,5-dimethoxybenzoyl chloride or
3,5-dimethoxybenzoyl chloride, respectively, in the presence of
anhydrous aluminium chloride in 1,2-dichloroethane at 110 C
(70W) for 2min. Treatment of 13 with triethylsilane in trifluoro-
acetic acid for 48 h afforded the corresponding methylene com-
pound 5.
Virtual screening studies
In search for allosteric inhibitors of the NS2B/NS3 protease, we car-
ried out virtual screening (VS) and docking studies. We focused
our VS studies against the allosteric site, of the enzyme42,43. To
our knowledge, only few protease allosteric inhibitors have been
reported30, and many of them are natural compounds that do not
possess drug-like properties30. We performed structure-based
screening studies on an open conformation of the NS2B/NS3 pro-
tease structure44 (pdb code: 2FOM)27 available at the protein data
bank webserver45. This structure of the NS2B/NS3 protease was
previously used in VS campaign in search for new allosteric
inhibitors43.
N
N NH2
R1
6: R1 = Me
7: R1 = Ph
R1 = Ph
a b
COOEtNC NHNH2
+ HCl. N
N N
R1 O2S
O2
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1: R1 = Me, R2 = Cl; 
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O
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O
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Scheme 1. Synthesis of the final compounds 1–3. (a) TEA, reflux, 7 h. (b) 4-Cl- or 4-NO2-C6H4SO2Cl, pyridine, 60 C, overnight. (c) LiOH, 50 C, 15min. (d) SnCl2, 80 C,
3 h. (e) 2,5-(OMe)2-THF, 100 C, 1 h. (f) benzoyl chloride, AlCl3, closed vessel, 110 C, 70 W, 4min.
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Compounds 4 and 5 shared virtually superimposable binding
modes: (a) the 2-methoxycarbonyl ester occupied the inner part of
the binding pocket and was stabilised by an H-bond with Asp152
side chain; (b) the indole NH formed an H-bond with Asn167; (c)
the indole ring arranged a series of hydrophobic contacts with
Val146, Leu149 and Leu76; (d) the methoxylphenyl moiety of both
inhibitors formed hydrophobic interactions with Trp83 and a pi-
cation interaction with Lys74. (Figure 1).
Biological activity
DENV NS5 RdRp inhibitors
Compounds 1–3 were evaluated in DENV-2 infected Huh-7 cells
by determining DENV RNA levels using specific qRT-PCR primer
targeting viral NS5 levels, normalised to cellular GADPH mRNA lev-
els. Compound 1 inhibited the DENV-2 with EC50 of
11.09 ± 0.21 mM and selectivity index (SI¼CC50/EC50 ratio) of 17.7.
Compound 2 bearing a benzoyl tail at position 2 of the pyrrole
potently inhibited DENV-2 with EC50 of 7.61 ± 0.36 mM and SI
>26.3. 1-Phenylpyrazole derivative compound 3 with the 4-nitro-
phenyl group showed potent anti-DENV-2 activity with EC50 of
5.66 ± 0.25 mM and SI> 35.3. Collectively, compounds 1–3 strongly
reduced DENV RNA level (Table 1 and Figure 2, panel A).
To confirm the anti-RdRp activity of 1–3, we performed a cell-
based RdRp reporter assay. The Huh-7 cells were transiently
expressed p(þ)RLuc-()DV-UTRDC-FLuc and DENV NS5 expression
vector pcDNA-NS5-Myc and then treated with the tested com-
pound. Our data showed that compounds 1–3 efficiently inhibited
DENV NS5 RdRp activity with EC50 of 8.07 ± 0.26, 7.22 ± 0.38 and
5.99 ± 0.30 mM (Table 1 and Figure 2, panel B). To further confirm
the inhibitory specificity of compounds 1–3 against NS5 RdRp
activity, we performed an enzyme-based FAPA assay. Our data
showed that compounds 1–3 exhibited direct-action against DENV
RdRp activity (Table 1) with EC50 of 7.78 ± 0.31, 5.34 ± 0.17 and
4.87 ± 0.24 mM, respectively, whose values correlated with results
of cell-based assay. Taken together, these results demonstrated
that compounds 1–3 attenuate DENV replication by directly inhib-
iting DENV RdRp activity.
DENV NS3 protease inhibitors
Huh-7 cells were infected with DENV-2 and then treated with pro-
tease inhibitors for 3 days and DENV RNA synthesis was evaluated
with specific qRT-PCR primers targeting viral NS5 gene.
Compounds 4 and 5 strongly inhibited the DENV-2 DNA replica-
tion with EC50s of 4.60 ± 0.03 mM and 7.28 ± 0.13 mM, respectively
(Table 2 and Figure 3, panel A). In addition, a cell-based DENV
protease reporter assay was used to characterise the protease spe-
cificity of compounds 4 and 5. Huh-7 cells were transfected
with pEG(MITA)SEAP and DENV protease expression vector
pcDNA-NS2B-GSG-NS3-Myc and then treated with 4 or 5. Both
compounds showed strong inhibitory activity against the DENV
protease with EC50 of 6.71 ± 0.20mM and 7.92 ± 0.62 mM, respect-
ively (Table 2 and Figure 3, panel B). We further performed an
enzyme-based assay to evaluate the inhibitory specificity of com-
pounds 4–5. The data showed that compounds 4–5 specifically
suppressed DENV protease activity with EC50 of 4.72 ± 0.3mM and
6.90 ± 0.11 mM, respectively (Table 2). In conclusion, the results
indicated that both compound 4 and 5 suppress DENV replication
by directly inhibiting DENV protease activity.
N
H
Cl
CCOMe
N
H
Cl
COOMe
OMe
R
OMe
N
H
Cl
COOMe
OMe
OMe
5
a b
12
(13)
O
4: R = OH; 13: R = H;
Scheme 2. Synthesis of the final compounds 4 and 5. (a) 4-OH-3,5-OMe2- or 3,5-OMe2-C6H4COCl, AlCl3, closed vessel, 110 C, 70 W, 2min. (b) TES, TFA, 48 h, rt.
Figure 2. Inhibition of DENV RNA replication and RdRp activity by compounds 1–3. Panel A. Huh-7 cells were infected with DENV-2 at a multiplicity of infection (M.O.I)
of 0.2 and followed by treatment with the DENV polymerase inhibitor for 3 days. The DENV RNA level was analysed by RT-qPCR with specific primer targeting viral NS5
gene, and relative viral RNA levels were normalised against cellular GADPH mRNA levels. Treatment of 50lM 20-C-methylcytidine (2CMC) direct against DENV RdRp
served as positive control. 0.1% DMSO (Mock) served as negative control. Panel B. Huh-7 cells were transfected with pEG(MITA)SEAP and pcDNA-NS2B-GSG-NS3-Myc
followed by incubation with each compound. The luciferase activity was analysed after 3 days treatment. Error bars denote the means ± SD of three independent experi-
ments. p< .05; p< .01.
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Evaluation of 3 and 4 in DENV-infected ICR-suckling mouse model
To access the antiviral activity of compound 3 and 4 in vivo,
6-day-old ICR-suckling mice were inoculated with 2.5 105 pfu of
DENV-2 by intracerebral injection and then were administered
with compound 3 (10mg/kg) or 4 (1mg/kg) by intracerebral injec-
tion at 1-, 3- and 5-day postinfection (dpi); inoculation of heat-
inactivated DENV-2 (iDENV) served as a mock control. The results
of clinical scores (Figures 4(A) and 5(A)) and body weight
(Figures 4(B) and 5(B)) showed that compound 3 or compound 4
treatment reduced DENV-induced pathology, including ruffled fur,
anorexia, severe paralysis, lethargy, on DENV-infected mice
within 4 to 6 dpi. Furthermore, compound 3 or 4 treatment
Figure. 3. Inhibition of DENV RNA and NS3-protease activity by compounds 4 and 5. Panel A. Huh-7 cells were infected with DENV-2 at a multiplicity of infection
(M.O.I) of 0.2 and followed by the treatment of each DENV protease inhibitors for 3 days. The DENV RNA level was analysed by RT-qPCR with specific primer targeting
viral NS5 gene, and relative viral RNA levels were normalised against cellular GADPH mRNA levels. Treatment of 50lM 20-C-methylcytidine (2CMC) direct against DENV
RdRp served as positive control. 0.1% DMSO (Mock) served as negative control. Panel B. Huh-7 cells were transfected with pEG(MITA)SEAP and pcDNA-NS2B-GSG-NS3-
Myc followed by incubation of each compounds, and the luciferase activity was analysed after 3 days treatment. Error bars denote the means ± SD of three independent
experiments. p< .05; p< .01.
Figure 4. DENV RdRp inhibitor 3 protected ICR-suckling mice from DENV infection. 6-day-old ICR-suckling mice were intracerebrally injected with heat-inactive DENV
(iDENV, n¼ 5) or active DENV (DENV, n¼ 4). Mice-receiving DENV were treated with 10mg/kg of compound 3 (n¼ 5) at 1, 3, 5 dpi. Panel A, clinical scores; Panel B,
body weight and Panel C, survival rate were recorded every day. Disease severity was scored as follow: 0: healthy, 1: slightly sick (reduced mobility), 2: inappetance,
3: weight loss and difficult to move, 4: paralysis, 5: death. Each group included 6 mice. Error bars denote the means± SD.
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significantly protected the mice against life-threatening DENV
infection, as compared to the untreated mice (Figures 4(C) and
5(C)). Collectively, these results demonstrated that both classes of
small molecules, targeting polymerase and protease
activities, inhibited DENV replication and represent prototypical
DAA molecules for further development through compound
modification.
Synergistic effect of NS5 RdRp inhibitor 3 and NS3 protease inhibi-
tor 4 against DENV replication
To examine whether combinational treatment of NS5 RdRp inhibi-
tor 3 and NS3 protease inhibitor 4 could synergistically inhibit
DENV replication, DENV-2-infected Huh-7 cells were cotreated with
3 and 4 at the indicated concentration for 3 days. As shown in
Figure 6, a synergistic inhibition of DENV replication was observed
with the 3 and 4 combination (lines 6–9), as compared to single-
compound treatment (lines 2–5).
Conclusions
We sought to design and characterise potential anti-DENV inhibi-
tors by targeting the viral enzymatic, NS5 RNA-dependent RNA
polymerase and the NS3 protease activities. We identified five
potential compounds demonstrating anti-DENV replication activity
without cytotoxicity. Two compounds targeting DENV NS3 prote-
ase and NS5 RdRp also exhibited anti-DENV activity in ICR-suckling
mouse model of DENV infection. Combination treatment exhibited
enhanced inhibition of DENV replication. Taken together, these
results demonstrate that both classes of small molecules inhibited
DENV replication and represent prototypical DAA molecules for
further development through compound modification.
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